Patients Who Stop Glp-1 Drugs Often Restart Or Try Alternatives

A ample real-world study shows that patients who extremity celebrated GLP-1–based weight-loss narcotics often return to curen aliases effort replacement therapies, helping explicate why mean weight regain aft discontinuation whitethorn beryllium smaller than expected.

Study: Obesity Treatments and Weight Changes successful Clinical Practice After Discontinuation of Semaglutide aliases Tirzepatide. Image credit: KaterynaBorodina/Shutterstock.com

Obesity curen has been revolutionized by nan preamble of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for illustration semaglutide, and dual GLP-1 RA/glucose-dependent insulinotropic polypeptide [GIP] receptor agonists for illustration tirzepatide. However, a study published in Diabetes, Obesity and Metabolism recovered that galore patients who discontinue these medications either restart curen aliases move to different options wrong a year.

Rising fame of GLP-1 therapies

Obesity affects about 40 % of American adults. It increases nan consequence of type 2 glucosuria mellitus (T2DM), non-alcoholic fatty liver, and obstructive slumber apnea 3-11-fold. The steep weight nonaccomplishment and important cardiovascular and metabolic benefits associated pinch narcotics for illustration semaglutide and tirzepatide underlie their accelerated emergence successful popularity.

According to different study, 1 successful 5 American women betwixt 50 and 64 years of property reported having tried 1 aliases much of these medications. Even so, anterior studies propose that up to 65 % of patients discontinue them wrong a year, and discontinuation has been associated pinch weight regain and reduced cardiometabolic benefits.

Examining diligent outcomes aft GLP-1 discontinuation

The study utilized a retrospective cohort creation and information from a ample healthcare strategy successful Ohio and Florida. All participants were overweight aliases obese and were connected injectable semaglutide aliases tirzepatide for either obesity aliases T2DM. The study focused connected patients who discontinued nan medicine wrong 3–12 months of initiation. The researchers examined curen patterns and weight changes pursuing discontinuation.

Many patients restart aliases move therapies aft discontinuation

The study included 7,938 patients who had started injectable semaglutide aliases tirzepatide. Most participants were White (75 %) and female (64 %), pinch a mean property of 55.7 years. At baseline, nan mean assemblage weight was 113 kg, and nan mean assemblage wide scale (BMI) was 39.5. Most patients were covered by backstage insurance.

Semaglutide was nan astir commonly prescribed medication. Overall, 46 % of patients initiated semaglutide for T2DM and 32 % for obesity. Tirzepatide was utilized little frequently, pinch astir 12 % of patients starting it for T2DM and 10 % for obesity.

Among those prescribed these medications for obesity, galore patients discontinued curen earlier reaching what nan authors picture arsenic capable therapeutic doses. The reasons for this shape stay unclear and warrant further investigation. The researchers statement that pricing structures whitethorn play a role, arsenic little doses are sometimes offered astatine reduced prices done self-pay channels. Future studies should research whether specified pricing models lend to deviations from recommended dose-escalation schedules.

Post-discontinuation, 19.6 % restarted nan original medication, while 35 % adopted different option: replacement medicine (27.4 %), healthcare sojourn for manner modification (13.7 %), and metabolic and bariatric room (0.6 %). These categories whitethorn not beryllium exclusive.

 Among patients who restarted their medications, 14 % received it for obesity and 24 % for T2DM. This whitethorn beryllium because security sum of nan usage of these agents is broader successful T2DM than for obesity. The mean clip to restarting was 177 days longer successful obesity than successful T2DM. Among replacement medications, astir nan aforesaid proportionality (<18 %) switched betwixt tirzepatide and semaglutide either way. Other medications included phentermine, topiramate, and bupropion.

Lifestyle-related visits included acquisition azygous aliases shared visits pinch healthcare professionals focused connected nutrition, exercise, and weight guidance (in isolation aliases arsenic portion of glucosuria management).

On average, patients treated for obesity mislaid 8.4 % of their original assemblage weight while connected nan medication, compared pinch a 4.4 % simplification among those treated for T2DM. One twelvemonth aft discontinuation, patients treated for obesity had gained 0.5 % of their baseline weight, whereas those treated for T2DM had mislaid a further 1.3 %.

However, these averages masked important variety betwixt individuals. Some patients regained important weight aft stopping treatment, while others maintained their weight nonaccomplishment aliases continued to suffer weight. Overall, 55 % of patients treated for obesity knowledgeable weight summation aft discontinuation, compared pinch 44 % of those treated for T2DM. These estimates were based connected patients pinch disposable follow-up weight measurements, representing a subset of nan afloat study population.

Further investigation is required to comparison various replacement treatments for post-GLP-1 RA aliases dual receptor agonist patients.

Strengths and limitations

The authors picture this arsenic nan first study to analyse obesity curen uptake successful detail, mixed pinch nan guidance of weight alteration during and aft discontinuation. It was based connected a ample sample, robust information sources, and a divers study population. The study besides drew connected linked physics wellness grounds and prescription-dispensing data, and included obesity curen astatine some master and generalist attraction settings.

Despite these strengths, nan study has respective limitations. The sample was drawn from a azygous healthcare strategy crossed 2 confederate states, which whitethorn limit nan generalizability of nan findings. In addition, each patients received some their first and follow-up attraction wrong nan aforesaid centers. Drug shortages during nan study play whitethorn besides person influenced curen patterns. The study could beryllium affected by residual confounding from unsupervised manner modifications, and importantly, nan reasons for curen discontinuation were not recorded.

Restarting aliases switching therapies communal aft GLP-1 discontinuation 

Among patients who discontinued tirzepatide aliases semaglutide wrong nan first twelvemonth of treatment, galore restarted nan original medicine aliases switched to different treatment. The weight alteration astatine 1 twelvemonth post-discontinuation was small, but depended heavy connected nan individual and whitethorn partially bespeak nan truth that galore patients resumed aliases transitioned to different weight-management therapies alternatively than remaining untreated.

Download your PDF transcript by clicking here.